These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 3031946

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 4. Dual effects of a new hypocalcemic agent, WR-2721, on cytoplasmic Ca2+ and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism.
    Larsson R, Nygren P, Wallfelt C, Akerström G, Rastad J, Ljunghall S, Gylfe E.
    Biochem Pharmacol; 1986 Dec 01; 35(23):4237-41. PubMed ID: 3024645
    [Abstract] [Full Text] [Related]

  • 5. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.
    Hirschel-Scholz S, Jung A, Fischer JA, Trechsel U, Bonjour JP.
    Clin Endocrinol (Oxf); 1985 Sep 01; 23(3):313-8. PubMed ID: 3000652
    [Abstract] [Full Text] [Related]

  • 6. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.
    Attie MF, Fallon MD, Spar B, Wolf JS, Slatopolsky E, Goldfarb S.
    J Clin Invest; 1985 Apr 01; 75(4):1191-7. PubMed ID: 2985652
    [Abstract] [Full Text] [Related]

  • 7. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
    Glover DJ, Shaw L, Glick JH, Slatopolsky E, Weiler C, Attie M, Goldfarb S.
    Ann Intern Med; 1985 Jul 01; 103(1):55-7. PubMed ID: 2988391
    [Abstract] [Full Text] [Related]

  • 8. S-2-(3-Aminopropylamino)ethyl phosphorothioic acid (WR-2721) in primary hyperparathyroidism.
    Morita M, Higashi K, Tajiri J, Sato T.
    Ann Intern Med; 1985 Dec 01; 103(6 ( Pt 1)):961. PubMed ID: 2998254
    [No Abstract] [Full Text] [Related]

  • 9. Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721.
    Hirschel-Scholz S, Charhon S, Rizzoli R, Caverzasio J, Paunier L, Bonjour JP.
    Kidney Int; 1988 May 01; 33(5):934-41. PubMed ID: 2839727
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA.
    J Bone Miner Res; 2002 Nov 01; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Recent advances on the thyrocalcitonin].
    Milhaud G.
    Ann Endocrinol (Paris); 1968 Nov 01; 29(5):563-75. PubMed ID: 4881133
    [No Abstract] [Full Text] [Related]

  • 14. Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
    Zingraff J, Bourdeau A, Clair F, Kindermans C, Buisson C, Manganella G, Sachs C, Drüeke T.
    Nephrol Dial Transplant; 1987 Nov 01; 2(1):48-52. PubMed ID: 3037448
    [Abstract] [Full Text] [Related]

  • 15. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).
    Glover D, Riley L, Carmichael K, Spar B, Glick J, Kligerman MM, Agus ZS, Slatopolsky E, Attie M, Goldfarb S.
    N Engl J Med; 1983 Nov 10; 309(19):1137-41. PubMed ID: 6312315
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
    Valeriote F, Tolen S.
    Cancer Res; 1982 Nov 10; 42(11):4330-1. PubMed ID: 6290032
    [Abstract] [Full Text] [Related]

  • 18. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul 10; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 19. Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats.
    Rizzoli R, Caverzasio J, Chapuy MC, Martin TJ, Bonjour JP.
    J Bone Miner Res; 1989 Oct 10; 4(5):759-65. PubMed ID: 2554691
    [Abstract] [Full Text] [Related]

  • 20. [Analysis of the toxicity and radioprotective effect of the chemical radioprotector WR 2721 in dogs (beagles). Part 2: Radioprotective effect of WR 2721 (author's transl)].
    Wagner M, Sedlmeier H, Metzger E, Wustrow T, Messerschmidt O.
    Strahlentherapie; 1980 Sep 10; 156(9):655-62. PubMed ID: 6254212
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.